# A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma

> **NCT06438614** · PHASE2 · COMPLETED · sponsor: **Fundació Sant Joan de Déu** · enrollment: 47 (actual)

## Conditions studied

- Refractory Neuroblastoma
- Soft Tissue Cancer

## Interventions

- **DRUG:** HITS
- **DRUG:** Naxitamab + GM-CSF cycles
- **DRUG:** NICE

## Key facts

- **NCT ID:** NCT06438614
- **Lead sponsor:** Fundació Sant Joan de Déu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-20
- **Primary completion:** 2023-07-20
- **Final completion:** 2023-10-24
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06438614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06438614, "A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06438614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*